Our Q2 2025 review of biopharma venture funding reflected a clear flight to quality, with capital concentrating on clinically validated platforms and de-risked science. While early-stage financing remained constrained, top investments continued to back mid- and late-stage companies with focused pipelines and near-term clinical milestones. Five standout deals raised over $740 million combined. Atlas Data Storage and AIRNA led the quarter, each securing $155 million.
Atlas is pioneering DNA-based data storage by integrating synthetic biology with semiconductor innovation. AIRNA will use its series B proceeds to launch clinical trials for AIR-001, targeting alpha-1 antitrypsin deficiency, and to expand its RNA editing platform. Atsena Therapeutics raised $150 million to advance its gene therapy for X-linked retinoschisis and broaden its AAV.SPR capsid platform. Azafaros secured $147 million for Phase 3 trials of its lead candidate for rare lysosomal storage disorders. Draig Therapeutics emerged with $140 million to launch Phase 2 trials for DT-101 in depression and progress two GABA-A receptor programs in CNS disorders.
In Q2 2025, biopharma therapeutics and platform companies raised $4.5 billion through 93 venture rounds, a clear decline from Q1 2025, which saw $6.7 billion raised across 110 rounds.
Compared to the previous quarter, deal volume fell by approximately 15%, total funding declined by about one-third, and the average round size dropped 23%, from $69 million to $53 million.
Biopharma Venture Totals by Series
In Q2 2025, biopharma venture funding totaled $4.5 billion across 93 rounds, down from $6.7 billion and 110 rounds in Q1. A sharp pullback in early-stage financing largely drove the decline, as seed funding fell 80% to $100 million, and series A dropped 63% to $1.2 billion, highlighting a tougher environment for new startups. In contrast, mid-stage investment held steady, with series B rising slightly to $1.4 billion and series C dipping to $600 million, indicating a focus on companies with validated preclinical progress. Late-stage funding also strengthened: series D and beyond increased to $800 million from $500 million, while unspecified private rounds doubled to $400 million.
Top Biopharma Technologies for Venture
In Q2 2025, venture funding remained focused on two dominant areas: small-molecule drug developers led with $1.9 billion across 34 rounds (42% of total funding), followed by biologics and nucleic acid-based platforms, which raised $1.3 billion across 31 rounds (29%). Funding for other modalities was more limited; gene therapy companies raised $334 million across five deals (averaging $67 million each), cell therapy secured $147 million in three rounds, and a single immunotherapy round brought in $20 million.
Top Venture Funding Activity in Q2 2025
Atlas Data Storage – Seed – $155M – May 2025
Atlas Data Storage secured $155 million in seed funding and acquired key technology assets from Twist Bioscience to advance its DNA-based data storage platform. Backers include ARCH Venture Partners, Deerfield Management, Bezos Expeditions, Tao Capital, Rsquared VC, Earth Foundry, In-Q-Tel, and others. The company is pioneering synthetic DNA as a next-generation data storage medium, citing unmatched data density, millennia-scale durability, and low-cost replication. Atlas integrates semiconductor chip innovation with enzyme engineering to enable scalable, high-throughput storage solutions at the intersection of synthetic biology and information technology.
AIRNA – Series B – $155M – April 2025
AIRNA, a transatlantic biotech specializing in RNA editing, raised $155 million in a series B round to support the clinical launch of its lead candidate, AIR-001, targeting alpha-1 antitrypsin deficiency (AATD). The round was led by Venrock Healthcare Capital Partners and Forbion Growth, with participation from RTW Investments, Arch Venture Partners, Nextech Invest, Forbion Ventures, ND Capital, and other undisclosed backers. This latest funding builds on AIRNA’s prior $60 million raise in July 2024. Proceeds will fund the upcoming Phase 1/2 trial for AIR-001 and advance AIRNA’s broader RNA editing pipeline.
Atsena Therapeutics – Series C – $150M – April 2025
Atsena Therapeutics, a clinical-stage gene therapy company focused on inherited eye diseases, raised $150 million in an oversubscribed series C round. The financing was led by Bain Capital Life Sciences, with new participation from Wellington Management and ongoing support from existing investors including Lightstone Ventures, Sofinnova Investments, Abingworth, and the Foundation Fighting Blindness. The funds will support Atsena’s lead candidate, ATSN-201, a gene therapy for X-linked retinoschisis (XLRS), a childhood-onset condition that leads to progressive vision loss. Proceeds will also fund Atsena’s preclinical pipeline and further development of its proprietary AAV.SPR capsid technology.
Azafaros – Series B – $146.6M – May 2025
Azafaros, a Dutch clinical-stage biotech developing treatments for rare neurological disorders, raised €132 million ($147 million) in an oversubscribed series B round. The financing was led by Jeito Capital, co-led by Forbion Growth, and included Seroba, Pictet Group, and returning investors Forbion Ventures, Schroders Capital, and BioGeneration Ventures. Proceeds will support the Phase 3 advancement of nizubaglustat, a brain-penetrant azasugar targeting lysosomal storage disorders such as Niemann-Pick disease Type C and GM1/GM2 gangliosidoses. Originally developed at Leiden University and Amsterdam UMC, nizubaglustat aims to provide a disease-modifying therapy for patients with limited treatment options.
Draig Therapeutics – Series A – $140M – June 2025
Draig Therapeutics, a neuroscience-focused biotech, emerged from stealth with £107 million ($140 million) in series A funding raised over the past nine months. The company will use the funds to initiate Phase 2 trials of its lead candidate, DT-101, for major depressive disorder by year-end, while advancing two additional programs toward clinical development in 2026. DT-101 targets the AMPA receptor, aiming to restore balance in brain signaling often disrupted in depression. Draig is also developing two preclinical candidates that modulate GABA-A receptors, a mechanism used in Sage Therapeutics’ approved treatments for postpartum depression.
Also check out Biopharma Therapeutics and Platforms M&A – Q2 2025 Review
